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With interestwe have read the article by Bernal-Bello et al., associat-
ing Pm/Scl antibodies with a higher risk of cancer in Systemic Sclerosis
(SSc) [1]. We appreciate the research this group performed as early de-
tection of malignancies in Systemic Sclerosis patients is important in
daily clinical practice.
Bernal-Bello et al. retrospectively analysed data of 432 consecutive
SSc patients and found a cancer prevalence of 12.2% (n = 53) with de-
creased survival for SSc patients with cancer. Pm/Scl antibody preva-
lence of 20.7% (n = 6/29) amongst SSc patients with cancer diagnosis
comparedwith 7.7% (n= 19/247) amongst SSc patients not being diag-
nosed with cancer is shown, together with increased cancer prevalence
amongst Pm/Scl patients (24%, n = 6/25). The authors conclude that
Pm/Scl antibodies are associated with malignancies in SSc and patients
being Pm/Scl antibody positive might benefit from comprehensive can-
cer screening [1]. The authors acknowledge the limitations of their de-
sign and suggest that their data should be replicated in other cohorts.
For example, not all included patients were serologically evaluated for
Pm/Scl positivity.
We took advantage of our prospective SSc cohort including all
patients that participate in the multidisciplinary day-care program
for SSc at the Leiden University Medical Center (LUMC) [2] in order
to evaluate the association between auto-antibodies and cancer
diagnosis. We re-evaluated 46 SSc patients with a history of malig-
nancy amongst 305 SSc patients with recent follow-up and at least
2 visits to our care pathway available. Sera of 280 patients were test-
ed for ANA screen, ENA (anti-SSA, anti-SSB, anti-centromere [ACA],
anti-topoisomerase [ATA], anti-RNP70, anti-U1RNP, anti-Smith,
anti-Jo), anti-U3RNP (fibrillarin), anti-Pm/Scl, anti-RNA polymerase
III (RNApIII), anti-Th/To and anti-Ku. In the remaining 25 patients,
Th/To and Ku was not determined and RNApIII, U3RNP and Pm/Scl
status was only determined if ANA screening was positive and ENA
screening did not reveal any disease-specific auto-antibodies, based
on the result in the first 280 patients. Prevalence of ACA was 38.0%
(n = 116), ATA 25.9% (n = 79), RNApIII 6.6% (n = 20), U3RNP
4.3% (n = 13), U1RNP 9.2% (n = 28), Pm/Scl 6.9% (n = 21), anti-
ThTo 1.6% (n = 5), anti-Ku 2.0% (n = 6), ANA-ENA- 4.3% (n = 13),
ANA+/ENA+, no specific SSc antibodies 9.5% (n = 29), N1 SSc
specific antibodies 8.9% (n = 27).http://dx.doi.org/10.1016/j.autrev.2017.05.023
1568-9972/© 2017 Elsevier B.V. All rights reserved.We evaluated distribution of clinical features and SSc-specific auto-
antibodies amongst SSc patients with and without malignancies
(Tables 1 and 2). Patients with cancer history were older, had longer
duration between first Raynaud phenomenon and first visit to the
day-care program, less often diffuse cutaneous disease and more often
pulmonary arterial hypertension (Table 1). There were no significant
differences in auto-antibody status between patients with or without
cancer history, although prevalence of anti-topoisomerase was
numerically lower (15.2%, n= 7 vs 24.3%, n= 63) and RNA polymerase
III (10.9%, n = 5 vs. 5.0%, n = 13) was numerically higher amongst
patients with malignancy.
Unfortunately, we could not replicate the finding of Bernal-Bello et
al. of Pm/Scl being more prevalent in SSc patients with a diagnosis of
cancer. For Pm/Scl frequencies were similar between patients with
(6.5%, n = 3) and without malignancy (6.9%, n = 18, p = 0.916).
Also our research is limited in its design as it concerns a single centre
cohort with limited sample size, especially for auto-antibodies with
lower prevalences in general. However, based on our data we cannot
advocate comprehensive cancer screening for Pm/Scl positive SSC
patients.
In addition, interestingly, the authors hypothesize that, as has been
shown for RNApIII antibodies [3], changed expression of the antigen
targeted by Pm/Scl in cancer tissue, might trigger the auto-immune re-
sponse, and result in Pm/Scl positive systemic sclerosis as a
paraneoplastic phenomenon. However, a consequence of auto-antibod-
ies directed against proteins that are highly or differently expressed in
tumour tissue might also be relevant in preventing tumour progression
and metastasis. In cancer, changed expression of proteins known as an-
tigens in SSc, is described not only for RNApIII and Pm/Scl, but is also de-
scribed for anti-topoisomerase (ATA) and anti-centromere (ACA) [4–6].
Indeed, the incidence of cancer in SSc is known to be increased com-
pared to the general population [7,8]. We therefore hypothesize that
prevalence of auto-antibodies differ between SSc patients with and
without cancer diagnosis according to their potency to fight cancer in
a preclinical stage.
More research in the association of auto-antibodies and occurrence
of cancer amongst SSc patients is warranted, as this may shine light on
disease pathogenesis in both diseases. In our opinion, antibody status
in its current form cannot help identifying which patients to screen for
cancer in the daily clinical setting, therefore clinical manifestations
should be leading in which patients to screen.Conflict of interest
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Table 1
Baseline characteristics of patients of the CCISS cohort with recent follow-up, auto-anti-







Male, %(n) 16.2 (42) 15.2 (7) 0.865
Age, mean (SD) 53.0 (14.1) 60.9 (13.7) 0.001














5 year-survival since first non-Raynaud
phenomenon, %(n)
79.1(204) 80.4(37) 0.902
Unknown, %(n) 17.1 (44) 15.2 (7) 0.767
dcSSc, %(n) 27.0 (70) 13.0 (6) 0.043





Lung involvement on HRCT, %(n) 54.4 (141) 56.5 (26) 0.794
Arrhythmia, %(n) 38.2 (95) 47.7 (21) 0.231
PAH, %(n) 2.7 (7) 13.0 (46) 0.001
N10% weight loss, %(n) 10.9 (28) 8.7 (4) 0.655
History of renal crisis, %(n) 4.3 (11) 2.2 (1) 0.503
DU, %(n) 23.2 (60) 23.9 (11) 0.912
CCISS cohort: Combined Care in Systemic Sclerosis cohort; Leiden University Medical
Center.
dcSSc - diffuse cutaneous Systemic Sclerosis, DU - digital ulcers, PAH - pulmonary arterial
hypertension.
Bold numbers indicate significance at p b 0.05.
Table 2
Auto-antibody prevalences of patientswith andwithout cancer history of the CCISS cohort








Anti-topoisomerase, %(n) 27.4 (71) 17.4 (8) 0.153
Anti-centromere, %(n) 37.8 (98) 39.1 (18) 0.868
Anti-RNA polymerase III, %(n) 5.8 (15) 10.9 (5) 0.200
Anti-U1RNP, %(n) 9.3 (24) 8.7 (4) 0.903
Anti-U3RNP, %(n) 4.6 (12) 2.2 (1) 0.447
Anti-Pm/Scl, %(n) 6.9 (18) 6.5 (3) 0.916
Anti-ThTo, %(n) 1.2 (3) 4.3 (2) 0.116
Anti-Ku, % (n) 1.9 (5) 2.2 (1) 0.913
N1 disease specific auto-antibody, %(n) 8.9 (23) 8.7 (4) 0.968
ANA/ENA negative, %(n) 4.6 (12) 2.2 (1) 0.447
ANA/ENA positive, no SSc specific
auto-antibody, %(n)
8.9 (23) 13.0 (6) 0.375
884 Auto-antibodies and cancer in systemic sclerosisReferences
[1] Bernal-Bello D, de Tena JG, Guillén-del Castillo A, Selva-O'Callaghan A, Callejas-
Moraga EL, Marín-Sánchez AM, et al. Novel risk factors related to cancer in scleroder-
ma. Autoimmun Rev 2017;16:461–8.
[2] Meijs J, Schouffoer AA, Ajmone Marsan N, Kroft LJ, Stijnen T, Ninaber MK, et al. Ther-
apeutic and diagnostic outcomes of a standardised, comprehensive care pathway for
patients with systemic sclerosis. RMD open 2016;2(1):e000159.
[3] Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Associ-
ation of the autoimmune disease scleroderma with an immunologic response to can-
cer. Science 2014;343(6167):152–7.
[4] Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger
RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type
specificity and implications for cancer chemotherapy. Cancer Res 1994;54(2):539–46.
[5] ZhangW, Mao J-H, ZhuW, Jain AK, Liu K, Brown JB, et al. Centromere and kinetochore
gene misexpression predicts cancer patient survival and response to radiotherapy
and chemotherapy. Nat Commun 2016;7.
[6] Marshall L, White RJ. Non-coding RNA production by RNA polymerase III is implicated
in cancer. Nat Rev Cancer 2008;8(12):911–4.
[7] Olesen AB, Svaerke C, Farkas D, Sørensen HT. Systemic sclerosis and the risk of cancer:
a nationwide population-based cohort study. Br J Dermatol 2010;163(4):800–6.
[8] Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis:




Jeska K. de Vries-Bouwstra
Department of Rheumatology, Leiden University Medical Center, Leiden,
The Netherlands
⁎Corresponding author at: Department of Rheumatology, C1-46, Leiden
University Medical Center (LUMC), P.O. Box 9600, 2300RC Leiden, The
Netherlands.
E-mail address: m.boonstra@lumc.nl (M. Boonstra).
10 May 2017
